1. Addition of 131I-MIBG to PRRT (90Y-DOTATOC) for Personalized Treatment of Selected Patients with Neuroendocrine Tumors
- Author
-
Stephen A. Graves, Yusuf Menda, David L. Bushnell, Thomas M. O'Dorisio, Kellie L. Bodeker, M. Sue O'Dorisio, Gideon K. D. Zamba, and Mark T. Madsen
- Subjects
Oncology ,medicine.medical_specialty ,Combination therapy ,business.industry ,Phases of clinical research ,030209 endocrinology & metabolism ,Neuroendocrine tumors ,medicine.disease ,03 medical and health sciences ,0302 clinical medicine ,medicine.anatomical_structure ,Internal medicine ,Radionuclide therapy ,Cohort ,90Y-DOTATOC ,medicine ,Dosimetry ,Radiology, Nuclear Medicine and imaging ,030212 general & internal medicine ,Bone marrow ,business - Abstract
Peptide receptor radionuclide therapy (PRRT) is an effective treatment for metastatic neuroendocrine tumors. Delivering a sufficient tumor radiation dose remains challenging because of critical-organ dose limitations. Adding 131I-metaiodobenzylguanidine (131I-MIBG) to PRRT may be advantageous in this regard. Methods: A phase 1 clinical trial was initiated for patients with nonoperable progressive neuroendocrine tumors using a combination of 90Y-DOTATOC plus 131I-MIBG. Treatment cohorts were defined by radiation dose limits to the kidneys and the bone marrow. Subject-specific dosimetry was used to determine the administered activity levels. Results: The first cohort treated subjects to a dose limit of 1,900 cGy to the kidneys and 150 cGy to the marrow. No dose-limiting toxicities were observed. Tumor dosimetry estimates demonstrated an expected dose increase of 34%–83% using combination therapy as opposed to 90Y-DOTATOC PRRT alone. Conclusion: These findings demonstrate the feasibility of using organ dose for a phase 1 escalation design and suggest the safety of using 90Y-DOTATOC and 131I-MIBG.
- Published
- 2021